Article

A Phase 1 Study of Novel Antiplatelet Agent to Overcome Pharmacogenomic Limitations of Clopidogrel

2024-03-26

Abstract excerpt

<h4>Background</h4> Clopidogrel is the most commonly prescribed thienopyridine as part of dual antiplatelet therapy for the treatment of cardiovascular diseases. However, Clopidogrel responsiveness shows variability based on CYP2C19 polymorphism. Therefore, we planned a study with an objective of evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of a novel thienopyridine antiplatelet agent AT-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c2e95f33-3769-55b8-a883-41fdda3d342d
DOI: 10.1101/2024.03.21.24304696

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Phase 1 Study of Novel Antiplatelet Agent to Overcome Pharmacogenomic Limitations of ClopidogrelDOI 10.1101/2024.03.21.24304696Read

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD).Semantic proximity Read

Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.Semantic proximity Read

Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.Semantic proximity Read

Adverse events in cardiovascular disease patients taking clopidogrel: impact of CYP2C19 genotype polymorphismsSemantic proximity Read

Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery DiseaseSemantic proximity Read

Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response.Semantic proximity Read

Ticlopidine with Ginkgo Biloba extract: a feasible combination for patients with acute cerebral ischemia.Semantic proximity Read

Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.Semantic proximity Read

Short-term efficacy and safety of personalized antiplatelet therapy for patients with acute ischaemic stroke or transient ischaemic attack: A randomized clinical trial.Semantic proximity Read

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read

A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.Semantic proximity Read

Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients.Semantic proximity Read